Purpose: Adaptation to host immune surveillance is now recognized as a hallmark of cancer onset and progression, and represents an early, indispensable event in cancer evolution. This process of evolution is first instigated by an immune selection pressure imposed by natural host surveillance mechanisms and may then be propagated by vaccination or other types of immunotherapy.

Experimental Design: We developed a system to simulate cancer evolution in a live host and to dissect the mechanisms responsible for adaptation to immune selection. Here, we show that the oxygen-sensitive α subunit of hypoxia-inducible factor 1 (HIF-1α) plays a central role in cancer immune adaptation under conditions of normal oxygen tension.

Results: We found that tumor cells gain HIF-1α in the course of immune selection under normoxia and that HIF-1α renders tumor cells resistant to lysis by tumor-specific cytotoxic T lymphocytes (CTL) in culture and in mice. The effects of HIF-1α on immune adaptation were mediated through VEGFA-dependent activation of the AKT and ERK signaling pathways, which induced an antiapoptotic gene expression network in tumor cells.

Conclusions: Our study therefore establishes a link between immune selection, overexpression of HIF-1α, and cancer immune adaptation under normoxia, providing new opportunities for molecular intervention in patients with cancer. Clin Cancer Res; 21(6); 1438–46. ©2015 AACR.

Translational Relevance

Our study identifies hypoxia-inducible factor 1 (HIF1) α as a key instigator of tumor immune adaptation, even under conditions of normal oxygen tension. We discovered that HIF1-α mediates immune adaptation through VEGFA-dependent activation of the AKT and ERK signaling pathways. Therefore, our study suggests that pharmacologic blockade of HIF1-α or these associated signaling pathways may represent an effective strategy for the clinical management of cancer, particularly in combination with immune-based modalities.

Immunotherapy has emerged as a promising approach for the clinical management of cancer. However, in many cases, it has been observed that the generation of a tumor-specific immune response does not translate into tumor regression in patients with cancer. A potential explanation for this is the overexpression by tumor cells of proteins that bestow them with enhanced survival, proliferation, and invasion capacity (1). In particular, hypoxia-inducible factor 1 (HIF1) is a key orchestrator of diverse biochemical pathways, from proliferation and survival to angiogenesis and invasion (2). Overexpression of HIF1 has been reported in virtually most of carcinomas (3), and HIF1 has been shown to drive cancer progression as well as resistance to chemotherapy and radiotherapy (2). Moreover, resistance of tumor cells to killing by NK cells or T cells has been reported to occur through HIF1 under hypoxia (4–9). Although HIF1 is a gateway to cancer progression, the manner in which it initially arises within tumor cells remains unknown. In fact, HIF1 is exquisitely sensitive to oxygen tension and is typically only present in stable form under hypoxia (10). Here, we found unexpectedly that stable expression of HIF1 in tumor cells occurs even under normal oxygen tension. We inferred that gain of HIF1 is a key element of cancer evolution that arises from selection pressure imposed by an antitumor immune response.

To explore this idea, we examined cancer evolution in the context of immune surveillance. Adaptation to immune defenses, in particular, those mounted by CD8+ cytotoxic T lymphocytes (CTL), has emerged as an early, indispensable, and host-intrinsic event in cancer progression (11). Thus, immune surveillance is an ideal selection pressure for the analysis of cancer evolution. We invented a system referred to as VICE, for Vaccination-Induced Cancer Evolution, in which variants of a parental tumor are derived through serial rounds of immune selection either in culture or in mice (12).

We used VICE to explore the role of HIF1 in cancer evolution under immune surveillance. Here, we show that the α subunit of HIF1 (HIF-1α) becomes markedly elevated during immune selection even under normoxia, and HIF-1α expression by tumor cells dictates the ability of cognate CTLs to control tumor growth. To our knowledge, gain of HIF-1α in tumor cells under normoxia in response to immune selection has not been previously reported. We found that the effects of HIF-1α on immune adaptation are transmitted through VEGFA-mediated activation of the AKT and ERK pathways, which induce the expression of a constellation of antiapoptotic molecules in tumor cells. Blockade of each of these pathways abrogated resistance of tumor cells to lysis by cognate CTLs, underscoring the importance of the HIF-1α/VEGFA axis in immune adaptation.

Cells

HPV-16 E7+ cells [TC-1, TC-1 P3, TC-1 P3 (A17), TC-1/no insert, and TC-1/HIF-1α] were used as a mouse tumor model. The production and maintenance of TC-1 (13) and TC-1 P3 A17 cells (14, 15) has been described previously. TC-1/HIF-1α cells were generated with the pMSCV/HIF-1α K532R vector (for TC-1/HIF-1α). For the production of human immune-resistant tumor cells, 106 CaSki (CaSki P0) cells were pulsed with 10 μg/mL HLA-A2–restricted MART-1 M27 peptide (AAGIGILTV) for 2 hours and mixed with KKM MART-1–specific human CD8+ T cells (gift from Dr. Cassian Yee, MD Anderson Cancer Center, TX, USA) in a 6-well plate at 1:1 ratio for 4 hours. Surviving CaSki cells were expanded and termed CaSki P1 cells. The above procedure was twice repeated to create the CaSki P3 cells. Nonspecific antigen NY-ESO-1 (SLLMWITQC) peptide-pulsed CaSki cells pulsed with the irrelevant peptide NY-ESO-1 (SLLMWITQC) were incubated with MART-1–specific human CD8+ T cells to derive control CaSki cells (CaSki N1 and CaSki N3). For hypoxia culture, cells were maintained at 1% O2 in a controlled atmosphere chamber (PLAS-LABS) with a gas mixture containing 1% O2, 5% CO2, and 94% N2 at 37°C. Cells were exposed to hypoxia for 14 hours before analysis unless otherwise indicated.

Mice

Six- to 8-week-old female C57BL/6 mice were acquired from Daehan Biolink. Mice were maintained and handled under protocols approved by the Korea University Institutional Animal Care and Use Committee (KUIACUC-2013-210; Seoul, Korea).

Chemicals and reagents

Pharmacologic agents used to inhibit signaling axes were LY294002 (Calbiochem Corp, 25 μM) for the PI3K pathway, SB203580 (Calbiochem Corp, 10 μM) for p38 MAPK pathway, and PD98059 (Stressgen, 10 μM) for the ERK pathway.

DNA and siRNA constructs

To produce the pMSCV/human HIF-1α vector, DNA fragments encoding the human HIF-1α K532R mutant were PCR amplified from pCMV/HIF-1α K532R (gift from Dr. Lee Mi Ok, Sejong University, Seoul, Korea) with primers (5′-ATGGAGGGCGCCGGCGGCG-3′ and 5′-CAGAATTCTCAGTTAACTTGATCCAAA-3′). The amplified fragments were cloned into the BglII/EcoRI sites of the pMSCV retroviral vector (Clontech). Synthetic siRNA specific for HIF-1α was synthesized with a 2′-O-ACE-RNA phosphoramides backbone (Invitrogen). The sequences of mouse HIF-1α siRNA are 5′-CCAGATCTCGGCGAAGTAA-3′ (sense) and 5′-UUACUUCGCCGAGAUCUGG-3′ (antisense), human HIF-1α siRNA are 5′-CCUAUAUCCCAAUGGAUGAUG-3′ (sense) and 5′-CAUCAUCCAUUGGGAUAUAGG-3′ (antisense). A total of 105 tumor cells were transfected in 6-well plates with 100 pmol of synthesized siRNAs with Lipofectamine 2000 (Invitrogen).

qRT-PCR

Total RNA was extracted with the RNeasy Mini Kit (Qiagen) and treated with DNase (Ambion). cDNA synthesis was performed with RT&Go Mastermix (MP Biomedicals), and real-time PCR was performed with Lightcycler FastStart DNA SYBR Green Master Mix (Roche) using mouse and human Vegfa-specific primers with the following sequences (Bioneer): mouse Vegfa, 5′-TGCACCCACGACAGAAGGA-3′ (forward) and 5′-GGCAGTAGCTTCGCTGGTAGAC-3′ (reverse); human Vegfa, 5′-CTGCTGTCTTGGGTGCATTGG-3′ (forward) and 5′-CACCGCCTCGGCTTGTCACAT-3′ (reverse). All data were normalized to expression level of β-actin mRNA.

Real-time qRT-PCR

Total RNA from TC-1 and CaSki cells was purified using TRIzol reagent (Invitrogen). Real-time PCR was conducted to detect Vegfa with TaqMan Universal SYBR Green Master Mix (Roche) using the mouse and human primer sets for Vegfa.

Western blot analysis

Samples probed with primary antibodies against phospho-AKT (Ser473), AKT, phospho-ERK (T202/Y204), ERK, p38 MAPK, BCL-w, BID, BIM, BAD, phospho-BAD (Ser 136), XIAP, Dual phospho-p38 MAPK (Cell Signaling Technology), HIF-1α, HIF-2α, Bcl-2, Bcl-xL, Bax, (Santa Cruz Biotechnology), BAK (BD Biosciences), or E7 (gift from Dr. Ju-Hong Jun, Seoul National University, Seoul, Korea). Antibodies were diluted 1:1,000, and bands were visualized by enhanced chemiluminescence (Elpis Biotech).

ELISA

VEGFA concentration in supernatant of TC-1 P0, P3 (A17) and CaSki P0, P3, N3 cells collected 48 hours after incubation was measured with mouse and human VEGFA Quantikine ELISA Kit (R&D Systems). Supernatant of HIF-1α siRNA-treated cells was collected after 72 hours. Supernatant of cells treated with VEGFA-neutralizing Ab (100 ng/mL) was collected after 24 hours. VEGFA concentration was normalized to the number of cells in each sample and depicted as pg of VEGFA per 106 cells.

Immunofluorescence microscopy

TC-1 P0, P1, P2, P3, N1, N2, and N3 cells were fixed in 4% paraformaldehyde for 10 minutes. Cells were washed with PBS, treated with 0.2% Triton X-100, and blocked for 1 hour in 1% BSA. Cells were incubated overnight in the presence of primary mAb against HIF-1α in a humidified chamber at 4°C. Cells were stained with Alexa Flour 555-labeled goat anti-rabbit IgG. Nuclei were stained with SYTOX Green (Invitrogen). Expression of HIF-1α was examined by confocal laser scanning microscopy (Carl Zeiss).

CTL-mediated apoptosis assay

TC-1 cells or CaSki cells were labeled with CFSE (10 μmol/L) in DMEM supplemented with 0.1% FBS. Cells were incubated for 10 minutes at 37°C and then pulsed with E7, NY-ESO-1, or MART1 peptide (10 μg/mL) for 1 hour, respectively. Tumor cells were then mixed with E7 or MART-1–specific CD8+ CTLs at a 1:1 ratio and incubated for 4 hours at 37°C. Cells were stained for active caspase-3 as an index of apoptosis and examined by flow cytometry. For CTL-mediated assay upon VEGFA blockade, VEGFA-neutralizing mAb (100 ng/mL) was added to cells 24 hours before the assay.

Tumor treatment experiments

C57BL/6 mice were inoculated subcutaneously with 105 TC-1 P0/no insert or TC-1 P0/HIF-1α cells. For immunization experiments as previously described (14), mice were administered with Vac-SEL days after tumor challenge. For adoptive transfer experiments, mice were administered with 2 × 106 E7-specific CTLs or isotonic saline control by tail vein injection 7 days after tumor challenge. Tumor dimensions (length and width) were measured with a calipers every 3 to 4 days, and tumor volume was calculated as length (mm) × width2 (mm2) × 0.52.

Statistical analysis

All data are representative of at least three independent experiments. Individual data points were compared using the Student t test. Statistical analysis was performed with SPSS version 17.0 software (SPSS Inc.). Values of P < 0.05 were considered statistically significant.

Tumor cells gain HIF-1α expression in the course of immune selection

To investigate the molecular evolution of cancer under selection pressure from an antitumor immune response, we created a system termed VICE (Vaccination-Induced Cancer Evolution), in which the tumor is subjected to serial rounds of immune selection by antigen-specific CD8+ CTLs (12). We administered C57BL/6 mice with vaccinia virus encoding the E7 antigen of human papillomavirus type-16 linked to the sorting signal of Lamp-1 (Vac-SEL) to elicit CD8+ CTLs against E7 (16). We then inoculated the mice with parental TC-1 tumor cells (P0), which harbor E7 antigen. Outgrowth tumor was excised and inoculated into naïve mice that previously received Vac-SEL. This process was repeated for three cycles to derive the P3 line, which was impervious to lysis by CTLs in vitro and in vivo. As a control, we performed this procedure in mice implanted with TC-1 cells without vaccination to generate N1, N2, and N3 cells without immune selection. Notably, expression of E7 as well as MHC class I was nearly identical in P3 and P0 cells, indicating that the immune resistance of P3 was not due to antigen loss (14). Although the HIF family of proteins has been implicated in chemotherapy resistance, its role in resistance to CTLs has not been previously examined under normal oxygen tension (2). We therefore probed for expression of HIF-1α and HIF-2α protein in P0 and P3 cells. Although there was no difference in HIF2α expression between P0 and P3 cells, HIF-1α was upregulated nearly 20-fold in P3 relative to P0 cells under normoxia; this was confirmed in a clone from the P3 line (A17; Fig. 1A). Under hypoxia, HIF-1α expression was also elevated in P3 relative to P0 cells (Fig. 1B). To verify evolution toward HIF-1α expression under immune surveillance, we measured HIF-1α levels in tumor cells at different stages of selection (P0 to P3). We observed a consistent and gradual increase in HIF-1α from P0 to P3; in contrast, HIF-1α levels remained constant in tumor cells at parallel stages without immune selection (N0 to N3; Fig. 1C). We thus conclude that HIF-1α expression is induced in tumor cells by immune selection.

Figure 1.

Immune selection induces HIF-1α in tumor cells. A, Western blot analysis of HIF-1α and HIF-2α expression in tumor cells before (P0) or after (P3) immune selection by CTLs. B, Western blot analysis of HIF-1α expression in P0 or P3 tumor cells in normoxia or hypoxia. C, top, quantification of HIF-1α expression in tumor cells at different stages of immune selection (P0 to P3). Parallel stages without selection are labeled as N1 to N3. Bottom, representative Western blot images. D, top, representative fluorescence microscopy images of nuclear HIF-1α in tumor cells. Bottom, quantification of the frequency of tumor cells with nuclear localization of HIF-1α.

Figure 1.

Immune selection induces HIF-1α in tumor cells. A, Western blot analysis of HIF-1α and HIF-2α expression in tumor cells before (P0) or after (P3) immune selection by CTLs. B, Western blot analysis of HIF-1α expression in P0 or P3 tumor cells in normoxia or hypoxia. C, top, quantification of HIF-1α expression in tumor cells at different stages of immune selection (P0 to P3). Parallel stages without selection are labeled as N1 to N3. Bottom, representative Western blot images. D, top, representative fluorescence microscopy images of nuclear HIF-1α in tumor cells. Bottom, quantification of the frequency of tumor cells with nuclear localization of HIF-1α.

Close modal

The overexpression of HIF-1α could be either due to elevated synthesis of basal HIF-1α by all tumor cells or to an increase the number of HIF-1α+ cells. To address this issue, we labeled P0 to P3 cells with fluorescence-labeled mAb against HIF-1α and determined the frequency of tumor cells with nuclear localization of HIF-1α by fluorescence microscopy. We observed a progressive increase in the frequency of nuclear HIF-1α+ tumor cells as immune selection progressed from the P0 to P3 stages (from 10%–80% of all tumor cells; Fig. 1D). Our results therefore demonstrate the molecular evolution of tumor cells toward HIF-1α under the immune selection pressure imposed by vaccination.

HIF-1α drives immune adaptation

Because HIF-1α is upregulated in tumor cells during immune surveillance, we reasoned that this expression might be responsible for immune adaptation. To test this, we transfected P3 cells with siRNA against either HIF-1α (siHIF-1α) or GFP control (siGFP), mixed the cells with E7-specific CTLs, and measured the frequency of apoptotic tumor cells. We observed a higher frequency of apoptotic tumor cells in the siHIF-1α- compared with the siGFP-transfected group (Fig. 2A), suggesting a role for HIF-1α in immune resistance. To confirm this, we transduced P0 cells with a human HIF-1α K532R mutant (P0/HIF-1α) that is stable in normoxia and characterized their phenotype (Fig. 2B). There was no significant difference in surface MHC class I expression between P0/HIF-1α cells or their empty vector–transduced counterparts (P0/no insert; Fig. 2C). Furthermore, the activation and viability of E7-specific CTLs were similar when mixed with HIF-1α or vector-transduced cells (Fig. 2D and E). However, the frequency of apoptotic tumor cells was lower among P0/HIF-1α compared with P0/no insert cells when mixed with either E7-specific CTLs or with granzyme B (Fig. 2E and F).

Figure 2.

HIF-1α facilitates tumor immune escape. A, E7+ tumor cells after immune selection (P3) were transfected with siRNA against HIF-1α or GFP control, mixed with E7-specific CD8+ CTLs, and the frequency of apoptotic tumor cells was determined by flow-cytometric analysis of caspase-3 activation. Left, Western blot analysis of HIF-1α expression in P3 cells transfected with siRNA against HIF-1α or GFP. Middle, representative flow-cytometric histograms. Right, bar graph quantification of the flow-cytometric data. Bottom right. B, Western blot analysis of HIF-1α and E7 expression in E7+ tumor cells before immune selection (P0) transduced with empty vector (P0/no insert) or HIF-1α (P0/HIF-1α). C, flow-cytometric histograms of MHC class I (H2-Db) expression in P0/no insert or P0/HIF-1α cells (grey outline). Black outline is isotype control. D, P0/no insert or P0/HIF-1α cells were mixed with E7-specific CTLs. Activation of CTLs was determined by flow-cytometric analysis of IFNγ secretion. E, the frequency of apoptotic CTLs (left) or tumor cells (right) from the reaction in part (D) was determined by flow cytometry analysis of caspase-3 activation. F, granzyme B was delivered into P0/no insert or P0/HIF-1α cells, and the frequency of apoptotic cells was determined by flow-cytometric analysis of caspase-3 activation. G, C57BL/6 mice were inoculated subcutaneously with 105 P0/no insert or P0/HIF-1α cells. Seven days later, mice received vaccination with vaccinia virus encoding E7 fused to the sorting signal of Lamp-1 (Vac-SEL). Tumor size was measured for 17 days. H, C57BL/6 mice were inoculated subcutaneously with 105 P0/no insert or P0/HIF-1α cells. Seven days later, mice received adoptive transfer through the tail vein of 2 × 106 E7-specific CTLs or isotonic saline control. Tumor size was measured.

Figure 2.

HIF-1α facilitates tumor immune escape. A, E7+ tumor cells after immune selection (P3) were transfected with siRNA against HIF-1α or GFP control, mixed with E7-specific CD8+ CTLs, and the frequency of apoptotic tumor cells was determined by flow-cytometric analysis of caspase-3 activation. Left, Western blot analysis of HIF-1α expression in P3 cells transfected with siRNA against HIF-1α or GFP. Middle, representative flow-cytometric histograms. Right, bar graph quantification of the flow-cytometric data. Bottom right. B, Western blot analysis of HIF-1α and E7 expression in E7+ tumor cells before immune selection (P0) transduced with empty vector (P0/no insert) or HIF-1α (P0/HIF-1α). C, flow-cytometric histograms of MHC class I (H2-Db) expression in P0/no insert or P0/HIF-1α cells (grey outline). Black outline is isotype control. D, P0/no insert or P0/HIF-1α cells were mixed with E7-specific CTLs. Activation of CTLs was determined by flow-cytometric analysis of IFNγ secretion. E, the frequency of apoptotic CTLs (left) or tumor cells (right) from the reaction in part (D) was determined by flow cytometry analysis of caspase-3 activation. F, granzyme B was delivered into P0/no insert or P0/HIF-1α cells, and the frequency of apoptotic cells was determined by flow-cytometric analysis of caspase-3 activation. G, C57BL/6 mice were inoculated subcutaneously with 105 P0/no insert or P0/HIF-1α cells. Seven days later, mice received vaccination with vaccinia virus encoding E7 fused to the sorting signal of Lamp-1 (Vac-SEL). Tumor size was measured for 17 days. H, C57BL/6 mice were inoculated subcutaneously with 105 P0/no insert or P0/HIF-1α cells. Seven days later, mice received adoptive transfer through the tail vein of 2 × 106 E7-specific CTLs or isotonic saline control. Tumor size was measured.

Close modal

To assess the role of HIF-1α in tumor immune adaptation in the setting of a host immune response, we inoculated C57BL/6 mice with P0/no insert or P0/HIF-1α, and then administered the mice with Vac-SEL 7 days later. Tumor growth was sharply accelerated in the vaccinated mice inoculated with P0/HIF-1α relative to P0/no insert cells (Fig. 2G). The presence of HIF-1α also rendered the tumor impervious to adoptive therapy with E7-specific CTLs (Fig. 2H). Notably, there was no significant difference in tumor growth between mice inoculated with P0/HIF-1α and P0/no insert cells without adoptive therapy, suggesting that HIF-1α facilitates cancer progression primarily by promoting immune adaptation.

HIF-1α turns on an antiapoptotic network in tumor cells through AKT and ERK signaling

We hypothesized that HIF-1α may cause immune adaptation by establishing an antiapoptotic state in tumor cells. To test this, we probed for the expression of a panel of pro- or antiapoptotic molecules in P3 cells transduced with siHIF-1α (relative to siGFP control) or in P0 cells transduced with HIF-1α (relative to empty vector control). We found that an array of antiapoptotic molecules, including Bcl-2, Bcl-xL, Bcl-W, XIAP, cIAP1, and cIAP2, were induced by HIF-1α (Fig. 3A). To elucidate the pathways by which HIF-1α controls expression of these molecules, we measured phosphorylation of AKT, ERK, and P38. We found that HIF-1α drives phosphorylation of AKT and ERK (Fig. 3B), and that pharmacologic inhibition of these pathways strongly reduces expression of antiapoptotic molecules (Fig. 3C) and renders tumor cells sensitive to lysis by CTLs (Fig. 3D). Therefore, HIF-1α-mediated immune adaptation occurs through the AKT and ERK signaling pathways, which trigger the activation of an antiapoptotic network within tumor cells.

Figure 3.

HIF-1α induces an anti-apoptotic program through the AKT and ERK pathways. A, Western blot analysis of a panel of pro- or anti-apoptotic factors in post-selection tumor cells (P3) transfected with siRNA against Gfp or Hif-1α, or in pre-selection tumor cells (P0) transduced with empty vector or Hif-1α (P0/Hif-1α). β-actin was included as an internal control. B, Western blot analysis of AKT, ERK, and p38 phosphorylation in P3 and P0 cells with indicated HIF-1α expression. C, Western blot analysis of anti-apoptotic molecules in P0/HIF-1α cells treated with LY-294002 (LY; AKT inhibitor, 25 μM), PD-98059 (PD; ERK inhibitor, 10 μM), SB-203580 (SB; p38 inhibitor, 10 μM), or DMSO control (Con). D, P0/HIF-1α cells treated as indicated were mixed with E7-specific CTLs. The frequency of apoptotic cells was determined by flow cytometry analysis of caspase-3 activation. All experiments were repeated independently at least three times.

Figure 3.

HIF-1α induces an anti-apoptotic program through the AKT and ERK pathways. A, Western blot analysis of a panel of pro- or anti-apoptotic factors in post-selection tumor cells (P3) transfected with siRNA against Gfp or Hif-1α, or in pre-selection tumor cells (P0) transduced with empty vector or Hif-1α (P0/Hif-1α). β-actin was included as an internal control. B, Western blot analysis of AKT, ERK, and p38 phosphorylation in P3 and P0 cells with indicated HIF-1α expression. C, Western blot analysis of anti-apoptotic molecules in P0/HIF-1α cells treated with LY-294002 (LY; AKT inhibitor, 25 μM), PD-98059 (PD; ERK inhibitor, 10 μM), SB-203580 (SB; p38 inhibitor, 10 μM), or DMSO control (Con). D, P0/HIF-1α cells treated as indicated were mixed with E7-specific CTLs. The frequency of apoptotic cells was determined by flow cytometry analysis of caspase-3 activation. All experiments were repeated independently at least three times.

Close modal

VEGFA ties HIF-1α expression to AKT and ERK signaling

We next sought to uncover the connection between HIF-1α expression and activation of AKT and ERK signaling. It has previously been shown that HIF-1α drives expression of its key target VEGFA, which is reported to induce the expression of antiapoptotic molecules in tumor cells (17, 18). We thus measured VEGFA expression and secretion in P0 versus P3 cells, and found both to be over 10-fold higher in P3 relative to P0 cells (Fig. 4A and B). We confirmed that HIF-1α controls expression of VEGFA by knocking down this transcription factor in P3 cells with siRNA (Fig. 4A and B), or by introducing it into P0 cells (Fig. 4C and D). To explore whether VEGFA triggers AKT and ERK signaling and the downstream antiapoptotic network, we incubated P3 or P0/HIF-1α cells with VEGFA blocking mAb and then measured AKT and ERK phosphorylation, as well as expression of antiapoptotic molecules. We observed reduced AKT and ERK phosphorylation among P3 or P0/HIF-1α cells incubated with α-VEGFA mAb relative to isotype control, together with lower expression of antiapoptotic molecules (Fig. 4E and F). Consistent with these data, P3 and P0/HIF-1α cells incubated with α-VEGFA mAb were more sensitive to killing by E7-specific CTLs compared with cells incubated with isotype control (Fig. 4G). We conclude that a core signaling axis linking HIF-1α, VEGFA, AKT/ERK, and an array of antiapoptotic molecules drives cancer immune adaptation.

Figure 4.

VEGFA facilitates HIF1a-mediated immune adaptation through activation of the AKT and ERK pathways. A and B, qRT-PCR analysis of VEGFA mRNA levels (A) or ELISA for VEGFA secretion (B) in tumor cells before (P0) or after (P3) immune selection (left), or in P3 cells transfected with siRNA against Gfp or Hif-1α (right). C and D, qRT-PCR analysis (C) or ELISA (D) of VEGFA in P0 cells transduced with empty vector or Hif-1α (P0/HIF-1α). E and F, Western blot analysis of AKT and ERK phosphorylation, as well as expression of antiapoptotic factors in P3 cells (E) or in P0/HIF-1α cells (F) pretreated with VEGFA blocking mAb or isotype control. G, P0/HIF-1α or P3 cells treated with or without α-VEGFA mAb were mixed with E7-specific CTLs. The frequency of apoptotic cells was determined by flow-cytometric analysis of caspase-3 activation. All experiments were repeated independently at least three times.

Figure 4.

VEGFA facilitates HIF1a-mediated immune adaptation through activation of the AKT and ERK pathways. A and B, qRT-PCR analysis of VEGFA mRNA levels (A) or ELISA for VEGFA secretion (B) in tumor cells before (P0) or after (P3) immune selection (left), or in P3 cells transfected with siRNA against Gfp or Hif-1α (right). C and D, qRT-PCR analysis (C) or ELISA (D) of VEGFA in P0 cells transduced with empty vector or Hif-1α (P0/HIF-1α). E and F, Western blot analysis of AKT and ERK phosphorylation, as well as expression of antiapoptotic factors in P3 cells (E) or in P0/HIF-1α cells (F) pretreated with VEGFA blocking mAb or isotype control. G, P0/HIF-1α or P3 cells treated with or without α-VEGFA mAb were mixed with E7-specific CTLs. The frequency of apoptotic cells was determined by flow-cytometric analysis of caspase-3 activation. All experiments were repeated independently at least three times.

Close modal

The HIF-1α-triggered VEGFA-AKT/ERK axis mediates immune adaptation of human cancer cells

Having established that the VEGFA-AKT/ERK axis induces HIF-1α-driven immune adaptation in a mouse model, we next sought to determine whether this is also true in human cancer. To do so, we pulsed parental CaSki human cervical cancer cells (P0) with a model peptide antigen, MART-1, (or an irrelevant antigen, NY-ESO-1 peptide) and then subjected these cells to immune selection with MART-1–specific human CTLs. After three rounds of selection, CaSki cells pulsed with MART-1 were termed P3, whereas those pulsed with irrelevant NY-ESO-1 peptide were termed N3. We mixed P0, P3, or N3 cells with MART-1–specific CTLs and determined the frequency of apoptotic tumor cells by flow-cytometric analysis of caspase-3 activation. We found that there were over two times less apoptotic P3 cells compared with either N3 or parental P0 cells, confirming, as expected, that immune selection of human cancer cells promotes immune adaptation (Fig. 5A). We also probed for HIF-1α expression in P0, P3, or N3 cells by Western blot analysis and observed over 10 times higher HIF-1α expression in P3 cells compared with either N3 or P0 cells (Fig. 5A). We also created two additional immune-resistant human tumor model systems by in vitro selection of parental MDA-MB-231 breast cancer cells or 526mel melanoma cells; we observed HIF-1α overexpression by immune-resistant cells compared with their parental counterparts in both of these systems (data not shown). Consistently, VEGFA mRNA level and protein secretion, AKT and ERK phosphorylation, and expression of the antiapoptotic factors cIAP-1 and cIAP-2, were upregulated in P3 cells relative to N3 and P0 cells as well (Fig. 5A and 5B and Supplementary Figs. S1 and S12). These results demonstrate that immune selection induces HIF-1α expression, VEGFA secretion, and activation of the AKT/ERK axis in human cancer cells, which prompts the expression of antiapoptotic factors. We found that silencing HIF-1α with siRNA reduced VEGFA secretion, AKT/ERK phosphorylation, and cIAP expression in CaSki P3 cells, showing that this sequence of signaling events is dependent on the presence of HIF-1α in immune-resistant human cancer cells (Fig. 5C and D). HIF-1α knockdown also rendered immune-resistant, MART-1-pulsed CaSki cells sensitive to lysis by human MART-1–specific CTLs (Supplementary Fig. S3). Likewise, HIF-1α knockdown in immune-resistant MDA-MB-231 or 526mel cells rendered them sensitive to these CTLs (data not shown). Furthermore, blockade of the VEGFA pathway with α-VEGFA mAb diminished AKT/ERK phosphorylation and cIAP expression, and restored sensitivity of P3 cells to MART-1–specific CTLs, illustrating that HIF-1α triggers the AKT/ERK axis, antiapoptotic signaling, and immune adaptation directly through VEGFA (Fig. 5E and F) in human cancer.

Figure 5.

HIF-1α-triggered VEGFA-AKT/ERK axis promotes immune adaptation in human cancer. Parental (P0) CaSki human cancer cells were pulsed with MART-1 peptide or irrelevant E7 peptide and subjected to selection with MART-1–specific human CTLs for three rounds to produce immune resistant (P3) or control (N3) cells. A, top, P0, P3, or N3 CaSki cells were incubated with MART-1–specific human CTLs, and the frequency of apoptotic tumor cells was determined by flow-cytometric analysis of caspase-3 activation. Middle, Western blot analysis of HIF1a expression in P0, P3, and N3 cells. Bottom, VEGFA concentration (pg/mL) in the supernatant of P0, P3, and N3 cells in culture. B, Western blot analysis of AKT and ERK phosphorylation, as well as expression of antiapoptotic proteins in P0, P3, and N3 cells. C, top, Western blot analysis of HIF1a expression in P3 cells transfected with siRNA against HIF-1α or GFP. Bottom, VEGFA concentration (pg/mL) in the supernatant of HIF-1α or GFP siRNA-treated CaSki P3 cells. D and E, Western blot analysis of AKT and ERK phosphorylation, as well as expression of antiapoptotic proteins in HIF1a or GFP siRNA and α-VEGFA mAb-treated CaSki P3 cells. F, control IgG or α-VEGFA mAb-treated CaSki P3 cells were pulsed with MART-1 peptide and mixed with MART-1–specific human CTLs. The frequency of apoptotic cells was determined by flow-cytometric analysis of caspase-3 activation.

Figure 5.

HIF-1α-triggered VEGFA-AKT/ERK axis promotes immune adaptation in human cancer. Parental (P0) CaSki human cancer cells were pulsed with MART-1 peptide or irrelevant E7 peptide and subjected to selection with MART-1–specific human CTLs for three rounds to produce immune resistant (P3) or control (N3) cells. A, top, P0, P3, or N3 CaSki cells were incubated with MART-1–specific human CTLs, and the frequency of apoptotic tumor cells was determined by flow-cytometric analysis of caspase-3 activation. Middle, Western blot analysis of HIF1a expression in P0, P3, and N3 cells. Bottom, VEGFA concentration (pg/mL) in the supernatant of P0, P3, and N3 cells in culture. B, Western blot analysis of AKT and ERK phosphorylation, as well as expression of antiapoptotic proteins in P0, P3, and N3 cells. C, top, Western blot analysis of HIF1a expression in P3 cells transfected with siRNA against HIF-1α or GFP. Bottom, VEGFA concentration (pg/mL) in the supernatant of HIF-1α or GFP siRNA-treated CaSki P3 cells. D and E, Western blot analysis of AKT and ERK phosphorylation, as well as expression of antiapoptotic proteins in HIF1a or GFP siRNA and α-VEGFA mAb-treated CaSki P3 cells. F, control IgG or α-VEGFA mAb-treated CaSki P3 cells were pulsed with MART-1 peptide and mixed with MART-1–specific human CTLs. The frequency of apoptotic cells was determined by flow-cytometric analysis of caspase-3 activation.

Close modal

The immune adaption of tumor cells in response to host immune defenses has emerged as a major driving force for cancer onset and progression (19). This process may occur through host-intrinsic events, such as the induction of tolerance to tumor antigen in tumor-specific CTLs or the recruitment of regulatory T cells or myeloid-derived suppressor cells to the tumor microenvironment (20). Alternatively, it may be controlled by tumor-intrinsic events, such as loss of antigen or gain of resistance to apoptosis (21, 22).

Here, we demonstrate cancer immune adaption in response to a selection pressure imposed by tumor-specific CTLs can be triggered via the HIF-1α/VEGFA pathway.

We found that expression of HIF-1α is profoundly upregulated in tumor cells subjected to immune selection by tumor-specific CTLs compared with those without selection. Expression of HIF-1α in tumor cells mediated resistance to lysis by CTLs both in a culture system and in mice in a tumor-intrinsic manner; the activation, survival, and function of CTLs were not influenced by the HIF-1α expression status of tumor cells. Furthermore, we did not detect any effects of HIF-1α expression on either MHC class I expression or antigen processing and presentation in tumor cells, suggesting that HIF-1α conferred a direct survival capacity to tumor cells. We found that HIF-1α upregulated expression of a constellation of antiapoptotic molecules—Bcl-xL, Bcl-W, XIAP, cIAP1, and cIAP2—in an AKT- and ERK-dependent manner. Furthermore, the effects of HIF-1α on AKT/ERK activation and tumor survival were mediated through VEGFA signaling, as VEGFA blockade abolished the antiapoptotic properties of HIF-1α.

It is well established that HIF-1α stability is exquisitely sensitive to oxygen tension, such that HIF1 is typically only present in abundant amounts under hypoxia. In the context of the tumor microenvironment, the core of a solid tumor mass is characterized by hypoxia, and thus, HIF1 expression is frequently high in these areas. However, our data suggest that HIF1 expression is not only limited to the core of the tumor mass, but may also extend into the marginal areas of the tumor (which have normal oxygen tension). What would be the benefit for tumor cells of HIF1 expression in these areas? We believe that, because tumor cells in the periphery are the first to encounter infiltrating lymphocytes, these cells would be the most susceptible to immune attack. Therefore, gain of HIF-1α by these marginal tumor cells would confer a strong “fitness” advantage, potentially explaining the evolution of tumor cells toward HIF1 expression even under normoxia in response to an immune selection pressure. Independently, HIF1 expression under normoxia would induce VEGF secretion and promote angiogenesis, thereby contributing to tumor progression (3, 23). For instance, HIF-1α under normoxia has been implicated in patients with highly vascularized hemangioblastoma, in which tumor cells immediately adjacent to blood vessels were found to stain intensely for HIF-1α (3, 23, 24). Future work should aim to explore these theories.

Finally, it is intriguing to consider our results in light of the “adaptation model” of the immune system that has been recently proposed (25), in which the expression of certain receptors and corresponding ligands by immune cells or peripheral tissue cells tunes the magnitude of the immune response. In this context, HIF-1α may represent an adaptation-inducing factor that turns on the expression of ligands that directly modulate lymphocyte activation. This will be an interesting area for future investigation.

In conclusion, our study unravels a signaling pathway composed of VEGFA, AKT/ERK, and antiapoptotic molecules linking HIF-1α to cancer immune adaptation. Inhibitors of each component of this pathway should, in principle, be effective against cancer, particularly as adjuvants for immune-based therapies.

No potential conflicts of interest were disclosed.

Conception and design: Y.-H. Lee, H.C. Bae, K.-H. Song, S.-K. Ye, T.-C. Wu, T.W. Kim

Development of methodology: Y.-H. Lee, H.C. Bae, K.H. Noh, T.-C. Wu

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y.-H. Lee, H.C. Bae, K.H. Noh, K.-M. Lee

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y.-H. Lee, H.C. Bae, K.H. Noh, K.-H. Song, C.-P. Mao, T.W. Kim

Writing, review, and/or revision of the manuscript: H.C. Bae, C.-P. Mao, T.-C. Wu, T.W. Kim

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.-K. Ye

Study supervision: K.-M. Lee, T.W. Kim

This work was funded by the National Research Foundation of Korea (2012R1A2A2A01007527, 2013M3A9D3045881, and 2009-0086652), the Korea Healthcare Technology R&D Project (HI11C-0052-030013), the United States NIH Cervical Cancer Specialized Program of Research Excellence (SPORE; P50 CA098252), Head and Neck Cancer SPORE (P50 CA96784-06), and R01 grant (CA114425-01). Chih-Ping Mao is a recipient of the NIH F30 Research Fellowship (CA177221).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Greaves
M
,
Maley
CC
. 
Clonal evolution in cancer
.
Nature
2002
;
481
:
306
.
2.
Semenza
GL
. 
Targeting HIF1 for cancer therapy
.
Nat Rev Cancer
2003
;
3
:
721
.
3.
Zhong
H
,
De Marzo
AM
,
Laughner
E
,
Lim
M
,
Hilton
DA
,
Zagzag
D
, et al
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
.
Cancer Res
1999
;
59
:
5830
.
4.
Barsoum
IB
,
Hamilton
TK
,
Li
X
,
Cotechini
T
,
Miles
EA
,
Siemens
DR
, et al
Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide
.
Cancer Res
2011
;
71
:
7433
.
5.
Barsoum
IB
,
Smallwood
CA
,
Siemens
DR
,
Graham
CH
. 
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
.
Cancer Res
2014
;
74
:
665
.
6.
Noman
MZ
,
Buart
S
,
Van Pelt
J
,
Richon
C
,
Hasmim
M
,
Leleu
N
,
Chouaib
S
. 
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis
.
J Immunol
2009
;
182
;
3510
.
7.
Noman
MZ
,
Janji
B
,
Kaminska
B
, Van
Moer
K
,
Pierson
S
,
Przanowski
P
,
Chouaib
S
. 
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression
.
Cancer Res
2011
;
71
;
5976
.
8.
Hasmim
M
,
Noman
MZ
,
Lauriol
J
,
Benlalam
H
,
Mallavialle
A
,
Rosselli
F
,
Chouaib
S
. 
Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells
.
J Immunol
2011
;
187
;
4031
.
9.
Noman
MZ
,
Buart
S
,
Romero
P
,
Ketari
S
,
Janji
B
,
Chouaib
S
. 
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells
.
Cancer Res
2012
;
72
;
4629
.
10.
Maxwell
PH
,
Wiesener
MS
,
Chang
GW
,
Clifford
SC
,
Vaux
EC
,
Cockman
ME
, et al
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
.
Nature
1999
;
399
:
271
.
11.
Schreiber
RD
,
Old
LJ
,
Smyth
MJ
. 
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
.
Science
2011
;
331
:
1565
.
12.
Lin
KY
,
Lu
D
,
Hung
CF
,
Peng
S
,
Huang
L
,
Jie
C
, et al
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion
.
Cancer Res
2007
;
67
:
1832
.
13.
Lin
KY
,
Guarnieri
FG
,
Staveley-O'Carroll
KF
,
Levitsky
HI
,
August
JT
,
Pardoll
DM
, et al
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
.
Cancer Res
1996
;
56
:
21
.
14.
Noh
KH
,
Kang
TH
,
Kim
JH
,
Pai
SI
,
Lin
KY
,
Hung
CF
, et al
Activation of Akt as a mechanism for tumor immune evasion
.
Mol Ther
2009
;
17
:
439
.
15.
Noh
KH
,
Lee
YH
,
Jeon
JH
,
Kang
TH
,
Mao
CP
,
Wu
TC
, et al
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype
.
Cancer Res
2012
;
72
:
1717
.
16.
Wu
TC
,
Guarnieri
FG
,
Staveley-O'Carroll
KF
,
Viscidi
RP
,
Levitsky
HI
,
Hedrick
L
, et al
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
.
Proc Natl Acad Sci USA
1995
;
92
:
11671
.
17.
Forsythe
JA
,
Jiang
BH
,
Iyer
NV
,
Agani
F
,
Leung
SW
,
Koos
RD
, et al
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
.
Mol Cell Biol
1996
;
16
:
4604
.
18.
Pidgeon
GP
,
Barr
MP
,
Harmey
JH
,
Foley
DA
,
Bouchier-Hayes
DJ
. 
Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells
.
Br J Cancer
2001
;
20
:
273
.
19.
Dunn
GP
,
Old
LJ
,
Schreiber
RD
. 
The three Es of cancer immunoediting
.
Annu Rev Immunol
2004
;
22
:
329
.
20.
Vesely
MD
,
Kershaw
MH
,
Schreiber
RD
,
Smyth
MJ
. 
Natural innate and adaptive immunity to cancer
.
Annu Rev Immunol
2001
;
29
:
235
.
21.
DuPage
M
,
Mazumdar
C
,
Schmidt
LM
,
Cheung
AF
,
Jacks
T
. 
Expression of tumour-specific antigens underlies cancer immunoediting
.
Nature
2012
;
482
:
405
.
22.
Igney
FH
,
Krammer
PH
. 
Immune escape of tumors: apoptosis resistance and tumor counterattack
.
J Leukoc Biol
2002
;
71
:
907
920
.
23.
Birner
P
,
Preusser
M
,
Gelpi
E
,
Berger
J
,
Gatterbauer
B
,
Hainfellner
JA
. 
Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications
.
Clin Cancer Res
2004
;
10
:
6567
.
24.
Helmlinger
G
,
Yuan
F
,
Dellian
M
,
Jain
RK
. 
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation
.
Nat Med
1997
;
3
:
177
82
.
25.
Manjili
MH
. 
The adaptation model of immunity
.
Immunotherapy
2014
;
6
:
59
.